FDA Approves Inavolisib Breast Cancer Treatment

By Rene Pretorius

October 15, 2024

The FDA’s approval of inavolisib breast cancer treatment in combination with palbociclib and fulvestrant is significant. It provides a new treatment option for a challenging patient population. This treatment is specifically for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. Patients eligible for this approval have experienced recurrence after completing adjuvant endocrine therapy.

The FoundationOne Liquid CDx assay was approved as a companion diagnostic device. This device helps identify which breast cancer patients are eligible for the inavolisib treatment regimen.

Efficacy Outcomes

– The primary efficacy outcome was assessed for progression-free survival (PFS) by investigators per RECIST version 1.1.
– The median PFS was 15.0 months (95% CI: 11.3, 20.5) for the inavolisib + palbociclib + fulvestrant arm, compared to 7.3 months (95% CI: 5.6, 9.3) for the placebo + palbociclib + fulvestrant arm (Hazard ratio 0.43 [95% CI: 0.32, 0.59], p-value < 0.0001).

Overall Survival

Although the interim analysis of overall survival did not achieve statistical significance, it suggested a trend in favor of the inavolisib regimen.

Regulatory Collaboration

This approval took place under Project Orbis, which is part of the FDA Oncology Center of Excellence. It involves collaboration with various international regulatory agencies, including the Australian Therapeutic Goods Administration (TGA), Health Canada, and Switzerland’s Swissmedic.

Reference url

Recent Posts

early aortic stenosis surgery
        

Earlier Surgery Recommended for Heart-Valve Patients: New Study Insights

💔 Are we waiting too long for heart health interventions?

A recent study suggests that patients with severe aortic stenosis may benefit significantly from earlier surgical intervention, overturning traditional ‘wait and see’ practices. This shift, utilizing minimally invasive techniques, could prove vital in reducing unexpected hospitalizations and improving overall outcomes for patients, especially seniors. Learn more about this pivotal research that may redefine treatment protocols in cardiology!

#SyenzaNews #HealthcareInnovation #ClinicalTrials #MedTech #HealthTech

cross-border health surveillance
   

Strengthening Cross-Border Health Surveillance in Africa

🌍 How can enhanced cross-border surveillance improve public health security in Africa?

Check out the Africa CDC’s newly launched Strategic Framework that aims to bolster collaboration and information sharing among African Union Member States. This initiative tackles the challenges of health threats linked to population movement by promoting robust systems for surveillance and response. Discover how these efforts can pave the way for safer communities across the continent!

#SyenzaNews #globalhealth #HealthcareInnovation #DigitalTransformation #HealthTech

regional immunization framework
              

Strengthening Immunisation in the Eastern Mediterranean: WHO Launches Regional Framework

🌍 How can strengthening immunisation in the Eastern Mediterranean transform public health?

The recent launch of the regional framework by WHO is a crucial step towards enhancing vaccine access and addressing disparities in coverage. This initiative, inaugurated in Doha, aims to save millions of lives by ensuring everyone has access to essential vaccines, especially in conflict-affected areas. Discover how this framework can pave the way for healthier communities!

#SyenzaNews #GlobalHealth #HealthForAll #HealthcareInnovation #Immunisation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.